ForPatients
*by Roche*

Duchenne Muscular Dystrophy (DMD)

# A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD)

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

| Trial Status | Trial Runs In | Trial Identifier |
|---|---|---|
| Completed | 1 Countries | NCT03375164 IRB17-00512 SRP-9001-101 |

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

## *Trial Summary:*

This is an open-label single-dose gene transfer therapy study evaluating the safety of delandistrogene moxeparvovec intravenous (IV) administration in boys with DMD. This study will consist of 2 Cohorts. Cohort A will include participants ages 3 months to 3 years, and Cohort B will include participants ages 4 to 7 years old. All participants in the study will receive IV delandistrogene moxeparvovec.

**Sarepta Therapeutics, Inc.**
Sponsor

**Phase 1/Phase 2**
Phase

**NCT03375164 IRB17-00512 SRP-9001-101**
Trial Identifiers

## *Eligibility Criteria:*

| Gender | Age | Healthy Volunteers |
|---|---|---|
| Male | >=3 Months & <= 7 Years | No |